SCRI Oncology Partners

Sometimes its the simple things that can make a difference in patient experience. We are so excited that we have the ability to give subcutaneous trastuzumab (Herceptin)/pertuzumab (Perjeta) instead of IV in our #Nashville practice SCRI Oncology Partners. Article out today in JCO Oncology Practice about the impacts of sub-q administration vs. IV administration of these #HER2 agents. Spoiler alert ⚠: SQ trastuzumab/pertuzumab translated to over 1 hour less ⏰ chair time for patients at EACH administration. Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2 Breast Cancer (ADEPT trial) | JCO Oncology Practice (ascopubs.org)

Do you want to hear the latest updates in Women's Oncology? Join us in Nashville on November 1-2 where we will discuss the latest advances and controversial topics in the field of breast #bcsm and gynecological cancers #gyncsm with kathleen moore. Free registration➡️hmpglobalevents.com/gduwo #GDUWO Great Debates & Updates

SCRI Oncology Partners and Meredith McKean were happy to offer this treatment option for #melanoma to patients. Now published in Journal of Clinical Oncology, boasting an over 60% response rate with fianlimab (LAG-3) with cemiplimab (PD-1). Adjuvant trial is ongoing and further trials in development. Clinical trials are a way to get access to tomorrow's cancer treatments today! https://lnkd.in/dJcMWyrd

Meredith McKean shares data around immunotherapy combinations for solid tumors at #ASCO24. We are lucky to be able to have clinical trials to offer our patients as one option for their cancer treatment at SCRI Oncology Partners!

#OncBrothers always make updates easily digestable for viewers! Happy to join Rohit Gosain, MD and Rahul Gosain, MD, MBA anytime to talk breast cancer! Sarah Cannon Research Institute SCRI Oncology Partners #ASCO24 #bcsm

I left #ASCO24 with new insights, connections, and perspectives. In the ever-evolving world of oncology, I relish the chance to collaborate with individuals who share the same passion to drive innovation forward.   I’m reinvigorated by the conversations had and discoveries shared at ASCO and how we at Sarah Cannon Research Institute can use them to inform ongoing research in lung cancer. I’ve summarized several innovative lung cancer trials that are advancing therapies, learn about the latest findings in the article below. SCRI Oncology Partners

Another introduction and the newest member of our team is: Vivek Subbiah, MD Chief, Early-Phase Drug Development Unity Sarah Cannon Research Institute He joined SCRI in 2023 and oversees SCRI’s nine drug development units and leads the expansion of early-phase capabilities and programs across SCRI’s growing research network.  Dr. Vivek Subbiah comes to SCRI from the University of Texas MD Anderson Cancer Center where he was an Associate Professor in the Department of Investigational Cancer Therapeutics. During his near 15-year tenure there, Dr. Vivek Subbiah held several leadership roles including Executive Director, Medical Oncology Research, MD Anderson Cancer Network as well as Clinical Medical Director, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine where he oversaw both the outpatient and inpatient clinical care delivery operations for the Phase I program. Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the US FDA, European Medicines Agency, and other agencies across the world. He has authored over 400 peer-reviewed publications in several high-impact journals such as The New England Journal of Medicine, Nature Medicine, Journal of Clinical Oncology, JAMA Oncology, Cancer Discovery, Lancet Oncology, Nature Reviews Clinical Oncology, Lancet Diabetes and Endocrinology, and Clinical Cancer Research, recipient of numerous awards like The Emil Frei III Award for Translational Research and editorial board of prestigious journals like JAMA Oncology and Annals of Oncology. After finishing his medical education in India, Dr. Vivek Subbiah completed a combined Residency program in Internal medicine and Pediatrics at Case Western Reserve University, MetroHealth, Cleveland, Ohio. He received board-certifications in both internal medicine and pediatrics and completed fellowships in both Adult and Pediatric oncology at MD Anderson. Dr. Subbiah also serves as a treating physician at SCRI Oncology Partners, where he attends to patients and provides them with the opportunity to participate in state-of-the-art cutting-edge clinical trials.  

Another MD introduction! This guy needs no introduction- Skip Burris, MD. President, Sarah Cannon Research Institute Howard A "Skip" Burris, III, MD, serves as president of Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials. Dr. Burris also serves as a treating physician at SCRI Oncology Partners where he can be found with his boots on the ground serving patients. In addition to his clinical expertise, Dr. Burris is known for his leadership in business strategy. Most recently, Dr. Burris helped to lead the formation of SCRI’s joint venture with US Oncology Research in 2022 to expand access to clinical trials for patients seeking the latest treatment options close to home. As a well-respected key opinion leader globally, Dr. Burris was elected by his peers to serve as the president of the American Society of Clinical Oncology (American Society of Clinical Oncology (ASCO)) 2019-2020 term and currently is chair of the Board for ASCO® Conquer Cancer Foundation community. Dr. Burris received his undergraduate degree at West Point, his medical degree from the University of South Alabama and performed his residency and fellowship in hematology/oncology at Brooke Army Medical Center in San Antonio. While there, he served as director of clinical research at the Institute for Drug Development of The Cancer Therapy and Research Center and was an associate professor at The University of Texas Health Science Center. He attained the rank of lieutenant colonel in the US Army, and among his decorations, he was awarded a Meritorious Service Medal with oak leaf cluster for his service in Operation Joint Endeavor.

SCRI Oncology Partners Sarah Cannon Research Institute physicians just got back from #ASCO24. It is humbling to be able to present data from these trials that advance care for patients to our colleagues from across the world. It also fills us with gratitude for our patient volunteers on trials that partner with us to make treatments better for tomorrow. It is so exciting that patients can access the newest therapies right here in #Nashvile! Across multiple disease subtypes- breast, GI, lung, GU, melanoma, GYN, H&N, and phase I rare tumors we were very encouraged about new afar from this year! #lcsm #bcsm #gyncsm David R. Spigel, MD Melissa Johnson Benjamin Garmezy Meredith McKean Meredith Sellers Pelster, MD, MSCI Erika Hamilton, MD Denise Yardley